Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR2 Anti-CD38 A2
- Development stage
- Discontinued
- Lead developer
- Sorrento Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR2 Anti-CD38 A2 is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Sorrento Therapeutics for the treatment of relapsed or refractory multiple myeloma (RRMM). The therapy utilizes T cells transduced with a retroviral vector to express a CAR featuring a fully human antibody (lambda light chain) specific for CD38, a glycoprotein highly expressed on malignant plasma cells. In clinical trials (SOR-CART-MM-001), the cells were administered following lymphodepletion with cyclophosphamide. While the phase 1 study demonstrated safety and some objective responses, the durability was limited, and the program has been succeeded by an allogeneic dimeric antigen receptor (DART) version.
- Other names
- anti-CD38 A2 CAR-T cellsanti-CD-38 A2 CAR-T cellsanti-CD 38 A2 CAR-T cellsCAR2 Anti-CD38 CAR-T cellsCAR-2 Anti-CD38 CAR-T cellsCAR 2 Anti-CD38 CAR-T cells
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on CAR2 Anti-CD38 A2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR2 Anti-CD38 A2.